Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 71

Sort by

Sort Order Select

Journal Articles

Efficacy and Safety of Inaticabtagene Autoleucel in Children with Relapsed/Refractory (R/R) B-cell Acute Lymphoblastic Leukemia in China

Shiyuan Wang, Xiaoming Liu, Yongjun Fang, Kailin Xu, Hongsheng Zhou, Fei Li, Xianmin Guan, Yingyi He, Yi Feng, Lulu Lyu, Qunhui Peng, Xiaofan Zhu, Jianxiang Wang

Blood (2024) 144 (Supplement 1): 7200.

https://doi.org/10.1182/blood-2024-201125

Published: 2024

Journal Articles

Maintenance Therapy of Golidocitinib, a JAK1 Selective Inhibitor, in Patients with Peripheral T Cell Lymphomas after First-Line Systemic Therapy: Updates of the Phase 2 Study (JACKPOT26)

Jie Jin, Liling Zhang, Liqun Zou, Zengjun Li, Huijing Wu, Keshu Zhou, Lihua Qiu, Liping Su, Kaiyang Ding, Hui Zhou, Li Yu, Fei Li, Qing Xiao, Wenyu Li, Lie Lin, Erhua Wang, Lijia Chen, Qingqing Cai

Blood (2024) 144 (Supplement 1): 6368.

https://doi.org/10.1182/blood-2024-211891

Published: 2024

Journal Articles

Safety and Efficacy of CD30-Directed Chimeric Antigen Receptor T Cell Therapy Plus Camrelizumab in Patients with Relapsed/Refractory CD30+ Lymphoma

Min Yu, Fancong Kong, Yulan Zhou, Tongcun Zhang, Fei Li, Ling Qi

Blood (2024) 144 (Supplement 1): 3465.

https://doi.org/10.1182/blood-2024-193279

Published: 2024

Journal Articles

The Treatment Pathways, Patient Characteristics and Outcomes in Patients with CD30-Expressing Lymphoma from China: A Multi-Center, Non-Interventional, Retrospective Study

Yi Miao, Wenyu Li, Kaiyang Ding, Fei Li, Xiaojing Yan, Xiaoxi Zhou, Caixia Li, Guohui Cui, Liqun Zou, Bing Xiu, Xiangxiang Zhou, Liansheng Zhang, Fuling Zhou, Hongmei Jing, Jianli Wang, Ziheng Guo, Jianyong Li

Blood (2024) 144 (Supplement 1): 6372.

https://doi.org/10.1182/blood-2024-201339

Published: 2024

Journal Articles

MYD88 Mutations in Chronic Lymphocytic Leukemia Exhibit Distinct Biological Behaviors and Prognostic Implications

Yuting Yan, Yulan Zhou, Weihao Chen, Jun Wang, Tingyu Wang, Ying Yu, Yujiao Jia, Zhen Yu, Lugui Qiu, Fei Li, Shuhua Yi

Blood (2024) 144 (Supplement 1): 4624.

https://doi.org/10.1182/blood-2024-207323

Published: 2024

Journal Articles

Spruce-TN CLL/SLL (cwCLL-002 study): An Ongoing Study of MRD-Guided Sonrotoclax Plus Zanubrutinib in Treatment-Naïve Chronic Lymphocytic Leukemia /Small Lymphocytic Lymphoma (CLL/SLL)

Shuhua Yi, Tingyu Wang, Fei Li, Jingdong Zhang, Xingli Zou, Yanping Ma, Lugui Qiu

Blood (2024) 144 (Supplement 1): 1875.1.

https://doi.org/10.1182/blood-2024-201175

Published: 2024

Journal Articles

Preliminary Efficacy and Safety of the CK1ε/PI3Kδ Dual Inhibitor HZ-H08905 in Patients with Relapsed and/or Refractory Peripheral T-Cell Lymphomas: Results from the Phase 1 HZ-H08905-101 Study

Juying Wei, Wenjuan Yu, Zhengming Jin, Keshu Zhou, Haiyan Yang, Fei Li, Lanfang Li, Bo Zhang, Miao Hu, Yanping Zhang, Xinglu Zhou, Jie Jin

Blood (2024) 144 (Supplement 1): 3057.

https://doi.org/10.1182/blood-2024-201210

Published: 2024

Journal Articles

Preliminary Efficacy and Safety of the CK1ε/PI3Kδ Dual Inhibitor HZ-H08905 in Patients with Relapsed and/or Refractory B-Cell Lymphomas: Results from the Phase 1 HZ-H08905-101 Study

Juying Wei, Wenjuan Yu, Zhengming Jin, Keshu Zhou, Haiyan Yang, Fei Li, Lanfang Li, Bo Zhang, Miao Hu, Yanping Zhang, Xinglu Zhou, Jie Jin

Blood (2024) 144 (Supplement 1): 3015.

https://doi.org/10.1182/blood-2024-201190

Published: 2024

Journal Articles

Efficacy and Safety of Axicabtagene Ciloleucel (Axi-cel) for the Treatment of Relapse/Refractory Non-Hodgkin's Lymphoma: Real-World Data in Chinese Population

Blood (2024) 144 (Supplement 1): 5115.

https://doi.org/10.1182/blood-2024-207186

Published: 2024

Journal Articles

A Phase 2 Clinical Trial of Anti-CD19 CAR-T (pCAR-19B) in Chinese Pediatric and Young Adult with Relapsed/Refractory (R/R) CD19+ B-ALL: The First Pivotal Study in an Asian Population

Blood (2024) 144 (Supplement 1): 4205.

https://doi.org/10.1182/blood-2024-206408

Published: 2024

Journal Articles

Safety and Efficacy in Patients with Advanced Lymphomas from a Global Phase 1a/1b, First-in-Human Study of CS5001, a Novel Anti-ROR1 ADC

Blood (2024) 144 (Supplement 1): 1739.

https://doi.org/10.1182/blood-2024-192979

Published: 2024

Journal Articles

ENO1 Activity Inhibition Induce Ferroptosis Susceptibility in BCR-ABL TKIs Resistant CML Cells through GPX4 Autophagy Degradation

Hongwei Peng, Wan Jiaqi, Jinfang Hu, Fei Li, Xintong Yang

Blood (2024) 144 (Supplement 1): 1338.

https://doi.org/10.1182/blood-2024-207012

Published: 2024

Journal Articles

Blockade of Gq Coupled P2Y6 Receptor Inhibited Myeloma Cells Proliferation and Survival Via Suppression of Camkiiγ-NF-Κb Pathway

Lifang Zou, Fei Li

Blood (2024) 144 (Supplement 1): 1883.

https://doi.org/10.1182/blood-2024-208994

Published: 2024

Journal Articles

A First-in-Human Phase 1/2 Study of the Menin-KMT2A(MLL1) Inhibitor BN104 in Adult Patients with Relapsed or Refractory Acute Leukemia

Blood (2024) 144 (Supplement 1): 2879.

https://doi.org/10.1182/blood-2024-198959

Published: 2024

Journal Articles

Nemtabrutinib, a Noncovalent Reversible BTK Inhibitor in Relapsed or Refractory Follicular Lymphoma: Results from the Phase 2 Bellwave-003 Study

Wojciech Jurczak, Isabelle Fleury, Antonio Pinto, Sanne Lugthart, Omur Gokmen Sevindik, Iryna Kryachok, Elizabeth Phillips, Fei Li, Chan Y. Cheah, Jing Yang, Yan Xu, Siyang Leng, Fangfang Lv

Blood (2024) 144 (Supplement 1): 1634.

https://doi.org/10.1182/blood-2024-201578

Published: 2024

Journal Articles

Orelabrutinib, Fludarabine, Cyclophosphamide, and Obinutuzumab (OFCG) for First-Line Treatment of Chronic Lymphocytic Leukemia: A Multicenter, Investigator-Initiated Study (cwCLL-001 Study)

Huayuan Zhu, Yi Miao, Shuchao Qin, Ming Liu, Yi Xia, Luomengjia Dai, Tonglu Qiu, Chong-Yang Ding, Hairong Qiu, Chun Qiao, Yujie Wu, Fei Li, Xiao Lu, Wei Xu, Lei Fan, Jianyong Li

Blood (2024) 144 (Supplement 1): 3244.

https://doi.org/10.1182/blood-2024-204881

Published: 2024

Journal Articles

Weekly Selinexor, Bortizomib and Dexamethasone (SVd) Versus Twice Weekly Bortizomib and Dexamethasone (Vd) in Chinese Patients with Relapsed and Refractory Multiple Myeloma (RRMM): Primary Analysis of Phase 3 Bench Study

Blood (2024) 144 (Supplement 1): 4748.

https://doi.org/10.1182/blood-2024-202893

Published: 2024

Journal Articles

Revealing the Hidden Impact: Essential Thrombocythemia (ET) and Its Effects on Ocular Blood Vessels through Optical Coherence Tomography Angiography (OCTA) Imaging

Jieyu Wang, Shixuan Wang, Fei Li

Blood (2024) 144 (Supplement 1): 4554.

https://doi.org/10.1182/blood-2024-210806

Published: 2024

Journal Articles

Azacitidine, Homoharringtonine and Cytarabine Combined with Granulocyte Colony-Stimulating Factor As Frontline Treatment for Older Patients with Acute Myeloid Leukemia: A Prospective, Multicenter, Single-Arm Phase III Study in China

Yafang Ma, Xiang Zhang, Jian Hou, Lijing Shen, Fei Li, Fancong Kong, Ying Lu, Guowei Li, Jie Jin, Wenjuan Yu

Blood (2024) 144 (Supplement 1): 4280.

https://doi.org/10.1182/blood-2024-203359

Published: 2024

Journal Articles

A predictive model for therapy failure in patients with chronic myeloid leukemia receiving tyrosine kinase inhibitor therapy

Blood (2024) 144 (18): 1951–1961.

https://doi.org/10.1182/blood.2024024761

Published: 2024

Includes: Supplemental data

NARROW

Efficacy and Safety of Inaticabtagene Autoleucel in Children with Relapsed/Refractory (R/R) B-cell Acute Lymphoblastic Leukemia in China

Maintenance Therapy of Golidocitinib, a JAK1 Selective Inhibitor, in Patients with Peripheral T Cell Lymphomas after First-Line Systemic Therapy: Updates of the Phase 2 Study (JACKPOT26)

Safety and Efficacy of CD30-Directed Chimeric Antigen Receptor T Cell Therapy Plus Camrelizumab in Patients with Relapsed/Refractory CD30+ Lymphoma

The Treatment Pathways, Patient Characteristics and Outcomes in Patients with CD30-Expressing Lymphoma from China: A Multi-Center, Non-Interventional, Retrospective Study

MYD88 Mutations in Chronic Lymphocytic Leukemia Exhibit Distinct Biological Behaviors and Prognostic Implications

Spruce-TN CLL/SLL (cwCLL-002 study): An Ongoing Study of MRD-Guided Sonrotoclax Plus Zanubrutinib in Treatment-Naïve Chronic Lymphocytic Leukemia /Small Lymphocytic Lymphoma (CLL/SLL)

Preliminary Efficacy and Safety of the CK1ε/PI3Kδ Dual Inhibitor HZ-H08905 in Patients with Relapsed and/or Refractory Peripheral T-Cell Lymphomas: Results from the Phase 1 HZ-H08905-101 Study

Preliminary Efficacy and Safety of the CK1ε/PI3Kδ Dual Inhibitor HZ-H08905 in Patients with Relapsed and/or Refractory B-Cell Lymphomas: Results from the Phase 1 HZ-H08905-101 Study

Efficacy and Safety of Axicabtagene Ciloleucel (Axi-cel) for the Treatment of Relapse/Refractory Non-Hodgkin's Lymphoma: Real-World Data in Chinese Population

A Phase 2 Clinical Trial of Anti-CD19 CAR-T (pCAR-19B) in Chinese Pediatric and Young Adult with Relapsed/Refractory (R/R) CD19+ B-ALL: The First Pivotal Study in an Asian Population

Safety and Efficacy in Patients with Advanced Lymphomas from a Global Phase 1a/1b, First-in-Human Study of CS5001, a Novel Anti-ROR1 ADC

ENO1 Activity Inhibition Induce Ferroptosis Susceptibility in BCR-ABL TKIs Resistant CML Cells through GPX4 Autophagy Degradation

Blockade of Gq Coupled P2Y6 Receptor Inhibited Myeloma Cells Proliferation and Survival Via Suppression of Camkiiγ-NF-Κb Pathway

A First-in-Human Phase 1/2 Study of the Menin-KMT2A(MLL1) Inhibitor BN104 in Adult Patients with Relapsed or Refractory Acute Leukemia

Nemtabrutinib, a Noncovalent Reversible BTK Inhibitor in Relapsed or Refractory Follicular Lymphoma: Results from the Phase 2 Bellwave-003 Study

Orelabrutinib, Fludarabine, Cyclophosphamide, and Obinutuzumab (OFCG) for First-Line Treatment of Chronic Lymphocytic Leukemia: A Multicenter, Investigator-Initiated Study (cwCLL-001 Study)

Weekly Selinexor, Bortizomib and Dexamethasone (SVd) Versus Twice Weekly Bortizomib and Dexamethasone (Vd) in Chinese Patients with Relapsed and Refractory Multiple Myeloma (RRMM): Primary Analysis of Phase 3 Bench Study

Revealing the Hidden Impact: Essential Thrombocythemia (ET) and Its Effects on Ocular Blood Vessels through Optical Coherence Tomography Angiography (OCTA) Imaging

Azacitidine, Homoharringtonine and Cytarabine Combined with Granulocyte Colony-Stimulating Factor As Frontline Treatment for Older Patients with Acute Myeloid Leukemia: A Prospective, Multicenter, Single-Arm Phase III Study in China

A predictive model for therapy failure in patients with chronic myeloid leukemia receiving tyrosine kinase inhibitor therapy

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only